Pre-market: Clearbridge Health (1H3.SI) falls 50% to S$0.001: liquidity concerns

Clearbridge Health Limited (1H3.SI) is a top pre-market loser after the stock fell 50.00% to S$0.001 on the Singapore Exchange (SES) as of this pre-market session on 14 Feb 2026. The sharp move follows weak 2024 revenue and loss updates and extremely thin trading liquidity. We examine why 1H3.SI stock dropped, how balance-sheet metrics and trading volumes amplify risk, and what forecast scenarios suggest for short- and medium-term recovery.

1H3.SI stock: pre-market price action and volume

Clearbridge Health (1H3.SI) opened at S$0.002 and traded down to S$0.001 in pre-market trade on SES, a 50.00% one-day move. Reported volume was 50,200 shares versus an average volume of 7,261,517.00 shares, highlighting very thin liquidity. Low participation amplifies price swings for 1H3.SI stock and raises execution risk for larger orders.

1H3.SI stock: company news and financial drivers

Public filings show Clearbridge’s 2024 revenue was S$9.90 million, down 4.84% year-on-year, with losses narrowing to S$3.61 million. That weak top-line and loss profile helps explain selling pressure. Market commentary and the company site indicate operations across Singapore, the Philippines and Malaysia. For more detail, see the company profile and financials source and Clearbridge’s site source.

1H3.SI stock: valuation and key ratios

On valuation metrics 1H3.SI stock shows a PB ratio of 0.13 and a price-to-sales of 0.58, reflecting a low market cap of S$4,295,821.00 and a book value per share of S$0.00850. The PE is negative and EPS is not meaningful. Current ratio is 1.73 which provides short-term cover, but interest coverage is negative at -3.82, underscoring earnings weakness.

1H3.SI stock: technicals and liquidity risks

Technicals for 1H3.SI stock show oversold indicators: RSI 37.56, CCI -155.56, and a one-day ROC at -50.00%. Average price over 50 days is S$0.00192 and 200-day is S$0.00263, both above the current price. With shares outstanding 4,295,820,825, low free float and thin volume create potential for wide intraday swings and unreliable support levels.

Meyka grade and analyst summary for 1H3.SI stock

Meyka AI rates 1H3.SI with a score of 61.51 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Third-party company rating (13 Feb 2026) gives a C and a Sell recommendation; that contrast reflects different weightings on valuation and liquidity. These grades are not guarantees and are for informational purposes only.

Outlook and price targets for 1H3.SI stock

Meyka AI’s forecast model projects a one-year mean scenario of S$0.009 and three-year scenario of S$0.024 for 1H3.SI stock. Versus the current S$0.001, the one-year projection implies theoretical upside of +800.00% but carries high uncertainty. Short-term realistic price targets from a risk lens are S$0.002–S$0.005 given volatility and average trading levels. Forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways: Clearbridge Health (1H3.SI) is a top pre-market loser on 14 Feb 2026 after a 50.00% drop to S$0.001 on SES in Singapore. The move reflects weak 2024 revenue of S$9.90 million, ongoing losses, and extremely low trading liquidity. Valuation metrics show a low PB ratio 0.13 but negative earnings and strained interest coverage. Meyka AI’s forecast model projects S$0.009 in one year, implying an upside of +800.00% from the current price; this is a model projection and not a guarantee. From a risk-first perspective, traders should treat 1H3.SI stock as highly volatile and illiquid. For investors we see three scenario bands: recovery to S$0.002–S$0.005 if sentiment stabilises, a model-driven rebound to S$0.009 under optimistic operational improvements, or deeper downside if liquidity dries up. We recommend monitoring upcoming earnings announcement on 27 Feb 2026 and watching volume and short-term cash metrics before increasing exposure. For full filings and company updates see the company site and financial summary source and our Meyka stock page Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.